Laura Stoppel - 04 Jun 2025 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director
Signature: /s/ Derek Meisner, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 04 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 05 Jun 2025, 18:05:34 UTC
Previous filing: 18 Jul 2024
Next filing: 26 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stoppel Laura	Director	C/O RA CAPITAL MANAGEMENT, 200 BERKELEY STREET, 18TH FLOOR, BOSTON	/s/ Derek Meisner, Attorney-in-Fact	05 Jun 2025	0001865119

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Award	$0	+12,800		$0.000000	12,800	04 Jun 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Stock Option (right to buy)	Award	$0	+19,500		$0.000000	19,500	04 Jun 2025	Common Stock	19,500	$1.07	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.
F3	The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.